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Published associations between dietary folate and bladder cancer risk are inconsistent. Biomarkers may provide more accurate
measures of nutrient status. This nested case–control analysis within the European Prospective Investigation into Cancer and
Nutrition (EPIC) investigated associations between pre-diagnostic serum folate, homocysteine, vitamins B6 and B12 and the
risk of urothelial cell carcinomas of the bladder (UCC). A total of 824 patients with newly diagnosed UCC were matched with
824 cohort members. Serum folate, homocysteine, and vitamins B6 and B12 were measured. Odds ratios (OR) and 95%
conﬁdence intervals (CI) for total, aggressive, and non-aggressive UCC were estimated using conditional logistic regression
with adjustment for smoking status, smoking duration and intensity, and other potential confounders. Additionally, statistical
interaction with smoking status was assessed. A halving in serum folate concentrations was moderately associated with risk of
UCC (OR: 1.18; 95% CI: 0.98–1.43), in particular aggressive UCC (OR: 1.34; 95% CI: 1.02–1.75; p-heterogeneity = 0.19).
Compared to never smokers in the highest quartile of folate concentrations, this association seemed only apparent among
current smokers in the lowest quartile of folate concentrations (OR: 6.26; 95% CI: 3.62–10.81, p-interaction = 0.07). Dietary
folate was not associated with aggressive UCC (OR: 1.26; 95% CI: 0.81–1.95; p-heterogeneity = 0.14). No association was
observed between serum homocysteine, vitamins B6 and B12 and risk of UCC. This study suggests that lower serum folate
concentrations are associated with increased UCC risk, in particular aggressive UCC. Residual confounding by smoking cannot
be ruled out and these ﬁndings require conﬁrmation in future studies with multiple measurements.
Introduction
Folate and related nutrients may inﬂuence cancer initiation
and progression through their role in the one-carbon metabo-
lism pathway, which is necessary for DNA synthesis, repair,
and methylation.1 They are present in a wide range of foods,
including fruit and vegetables. There is limited suggestive
evidence that fruit and vegetable consumption is inversely asso-
ciated with bladder cancer risk.2 Case–control studies have
What’s new?
Results of studies on dietary folate and bladder cancer risk are inconsistent. This nested case-control analysis within the
European Prospective Investigation into Cancer and Nutrition is one of the ﬁrst prospective study investigating associations
between pre-diagnostic serum folate, homocysteine, vitamins B6 and B12 and the risk of urothelial cell carcinomas of the
bladder (UCC). This study suggests that lower serum folate concentrations are associated with increased risk of UCC, in
particular aggressive UCC.
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shown that intake of folate and other B-vitamins may also
reduce risk of bladder cancer, but results from prospective stud-
ies are inconsistent.3 This inconsistency may partly be due to
misclassiﬁcation of self-reported intake. Thus far, only two stud-
ies used circulating blood concentrations of folate, which reﬂect
both dietary and supplemental intakes. A case–control study
found an inverse association for plasma folate concentrations
and bladder cancer risk,4 but may be biased by changes in blood
concentrations after diagnosis. A recent nested case–control
study investigating pre-diagnostic plasma folate concentrations
found no association with bladder cancer risk.5
In addition to folate status assessment methods, the hetero-
geneous nature of bladder cancer may contribute to inconsis-
tent study results. Urothelial cell carcinoma (UCC), the most
common morphological type of bladder cancer, varies in natu-
ral history. Stratiﬁcation into different subgroups according to
stage and grade may help to identify risk factors involved in
different UCC pathways. It has been suggested that associa-
tions with cigarette smoking and employment in a high-risk
occupation, the most well-known risk factors for UCC,6 are
stronger for bladder tumours with a higher stage and grade.7–9
However, other studies did not ﬁnd different associations by
tumour stage.10,11 Previous ﬁndings from our group have shown
that plasma concentrations of carotenoids may particularly inﬂu-
ence the risk of bladder tumours with a higher stage and grade.12
Interestingly, some studies showed that global DNA methylation
may also be differently associated with UCC subtypes, with
higher methylation levels associated with a reduced risk of lower
stage and grade tumours13,14 and intermediate methylation levels
with a reduced risk of higher stage and grade tumours.14 Thus,
the unavailability of folate-derived methyl groups may inﬂuence
the risk of UCC through altered DNA methylation.
This nested case–control analysis within the European
Prospective Investigation into Cancer and Nutrition (EPIC) is
one of the ﬁrst prospective studies that investigated associations
between pre-diagnostic serum compounds involved in one-
carbon metabolism (folate, homocysteine, vitamin B6, vita-
min B12) and the risk of UCC.
Subjects and Methods
Study population and data collection
The design and methods of the EPIC study have been described
in detail previously.15,16 Brieﬂy, EPIC is a cohort study compris-
ing more than half a million people recruited in 10 European
countries. Between 1992 and 2000, standardised questionnaires
on diet, lifestyle questionnaires, and medical history were col-
lected at enrolment.15–17 Intakes of dietary folic acid and vitamins
B2, B6, and B12 were estimated using the updated EPIC Nutrient
Data Base, obtained after standardisation from country-speciﬁc
food composition tables.17 Study centres collected and stored
blood samples according to a standardised protocol.15 Biological
samples (74% of all respondents donated samples) are stored at
the International Agency for Research on Cancer (IARC, Lyon,
France) in −196 C liquid nitrogen for all countries except
Denmark (−150 C, nitrogen vapour) and Sweden (−80 C,
freezers). While protected from light after blood donation, the
blood samples from Oxford and Norway were exposed to ambi-
ent temperatures for up to 48 h. As B-vitamin concentrations are
partly degraded by such handling, the samples from these centres
were excluded from the present analyses.15,16 All participants
gave written informed consent, and the study was approved by
the Institutional Review Board of IARC and the local ethics com-
mittees in the participating countries.
Nested case–control design and selection of participants
Ascertainment of newly diagnosed bladder cancer patients has
been described previously.12 Participants were followed from
study entry until a ﬁrst primary bladder cancer diagnosis (code
C67 according to the ICD–Oncology, third edition), end of
follow-up (between 2002 and 2005 in different countries), last
known contact date, cancer diagnosis, or death. Only (papillary)
urothelial cell carcinomas (UCC morphology codes 8,120 and
8,130) were included in the analyses, as these comprise more
than 90% of bladder cancers. Pathology reports of UCC cases
were collected from each centre to obtain information on stage
and differentiation grade of the tumour. Stage T1 and higher,
carcinoma in situ, or WHO grade 3 carcinomas were classiﬁed
as aggressive UCCs, whereas stage Ta grades 1 or 2 were classi-
ﬁed as non-aggressive UCCs.18 Ninety-two percent of the cases
could be classiﬁed as aggressive or non-aggressive UCC.
Each case was matched to one control by incidence density
sampling from all cohort members alive without a cancer diag-
nosis of any kind (except non-melanoma skin cancer) at the time
of diagnosis of the case. Controls were randomly selected from
the population at risk at the time of diagnosis of the case.19
Matching criteria were sex, age at time of enrolment ( 3 years),
study centre, date of blood collection ( 3 months), time of day
of blood collection ( 2 h) and fasting status at the time of
blood collection (< 3, 3–6, and > 6 h since last meal). Matched
controls were unavailable for 11 cases and these individuals were
excluded from analyses. Case sets including participants with
missing blood samples (n = 110), no information on follow-up
(n = 6) or smoking history (n = 15), from Oxford or Norway
centre (n = 49), or including cases with other morphology codes
than 8,120 and 8,130 (n = 78) were also excluded. Our study
included 824 pairs of ﬁrst primary UCC cases and their matched
controls.
Laboratory assays
Serum samples were analysed at the National Institute for
Public Health and the Environment (Bilthoven, The Nether-
lands) for folate (vitamin B9) and vitamin B12 (cobalamin)
by using an Access-2 immunoanalyzer (Beckman-Coulter).
Vitamin B6 (pyridoxal-5-fosfate) was determined by reversed-
phase HPLC analysis with ﬂuorescence detection using a kit of
Chromsystems (Munich, Germany). Vitamin B2 (riboﬂavin)
could not be assayed because the amount of available blood was
insufﬁcient. The HPLC equipment was from Varian Association
Vrieling et al. 2351
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(Middelburg, the Netherlands) equipped with a ﬂuorescence
detector from Jasco (Separations, Hendrik-Ido-Ambacht, The
Netherlands). Homocysteine concentrations were determined
with an enzyme cycling assay (Dialab, Neudorf, Austria) on an
LX20-Pro autoanalyser (Beckman-Coulter, Woerden, The Neth-
erlands). For quality control, one control sample with concentra-
tions similar to the mean concentrations in controls was added
to each batch of samples to assess interbatch reproducibility.
There were 21 batches. Coefﬁcients of variation for these quality-
control samples were 6.1% for folate, 3.4% for homocysteine,
3.5% for vitamin B6, and 7.2% for vitamin B12. To minimise the
inﬂuence of batch-to-batch variation, cases were analysed in the
same analytic batch as their matched controls. Laboratory techni-
cians were blinded to the case–control status of the samples, and
biochemical analyses were done in one laboratory, with avoid-
ance of between-laboratory method variability.
Statistical analysis
Odds ratios (OR) and 95% conﬁdence intervals (95% CI) for
UCC risk in relation to serum concentrations and dietary
intakes were calculated using conditional logistic regression
models stratiﬁed by the case–control set.20 ORs were calculated
using quartiles with cutoffs based on the distribution of serum
and/or dietary intake levels of folate, homocysteine, vitamins
B2, B6 and B12 in control subjects. We derived probability
values for a linear trend across quartiles from regression models
by using the median log2-transformed serum and/or dietary
levels within quartiles as a continuous variable.21 The data were
also analysed as log2-transformed continuous variables. The
ORs of these log2-transformed variables correspond to the
increase in UCC risk with the halving of the serum concentra-
tion or dietary intake. To investigate departure from linearity,
we also included a quadratic term for each log2-transformed
serum and dietary intake level and tested for a quadratic trend
using the likelihood ratio test.
All models were adjusted for smoking status (never, former,
current), duration of smoking (years), and lifetime intensity of
smoking (cigarettes/day). The ﬁnal models were additionally
adjusted for energy intake (continuous), consumption of pro-
cessed or red meat (continuous), alcohol intake (continuous),
physical activity (inactive, moderately inactive, moderately
active, active, unknown), BMI (continuous), and educational
level (primary school or less, technical-professional school, sec-
ondary school, university, unspeciﬁed). Occupational history
was not included in the ﬁnal models, since it was only available
for a subset of the population and did not affect the β estimates
of serum and/or dietary levels within this subset. We also tested
whether further adjustment for the other B-vitamins and homo-
cysteine changed the risk estimates. As previous ﬁndings in the
same study population suggest a reduced UCC risk with higher
concentrations of the sum of plasma carotenoids12 and an
increased UCC risk with plasma α-tocopherol (data not shown),
we also tested further adjustment for these micronutrients.
Polytomous conditional logistic regression stratiﬁed by the
case–control set was used to assess the association of serum
concentrations and dietary intakes with aggressive and non-
aggressive UCC as separate endpoints.22 Statistical heterogene-
ity of associations across these subtypes was assessed with a
likelihood ratio test, comparing a model in which the associa-
tion could vary by subtype versus a model assuming the same
association across subtypes.
Because smoking may not only confound but also modify
the association,23,24 joint effects were determined for quartiles
of serum one-carbon metabolism biomarkers in combination
with smoking status (never, former, current) in relation to
UCC risk. The combined category of high serum concentra-
tions with never smoking was chosen as reference. Statistical
interaction on a multiplicative scale was tested by introducing
a product term between serum one-carbon metabolism bio-
markers (quartiles) and smoking status. Similar models were
used to test for interactions with BMI,25 gender and alcohol
intake.26 Joint effects of folate, homocysteine, vitamin B6 and
vitamin B12 were also conducted to evaluate whether the
measured analytes interacted with each other. Analyses of
joint effects were performed unadjusted and adjusted for
smoking status, duration of smoking and lifetime intensity of
smoking. To evaluate whether preclinical disease may have
inﬂuenced the results, analyses were repeated after exclusion
of cases along with their matched controls who were diag-
nosed within 2 years after recruitment (n = 136 pairs).
All statistical analyses were performed with SAS software
(version 9.2, SAS Institute Inc). For all analyses, two-sided
p < 0.05 was considered statistically signiﬁcant.
Results
Baseline characteristics of cases diagnosed with UCC and their
matched controls are shown in Table 1. UCC cases were more
likely to smoke, were slightly less educated, reported a higher
intake of alcohol and red and processed meat, and consumed
less fruit and vegetables. Spearman correlations between the
individual serum biomarkers and between the serum bio-
markers and the dietary intake levels of the B-vitamins were
statistically signiﬁcant but generally weak, ranging from −0.23
to 0.38.
A halving in serum folate concentrations was moderately
associated with increased risk of UCC (OR: 1.18; 95% CI:
0.98–1.43) (Table 2). When stratiﬁed by prognostic subgroups
of UCC, a halving in serum folate was positively associated
with aggressive UCC (OR: 1.34; 95% CI: 1.02–1.75). Serum
folate was not associated with non-aggressive UCC (OR: 1.03;
95% CI: 0.78–1.37), and no statistically signiﬁcant heterogene-
ity by tumour subtype was observed (p-heterogeneity = 0.19).
Quartile analyses showed similar results. The associations of
folate were similar for models only adjusted for smoking
(Supporting Information Table S1) and remained after adjust-
ing the ﬁnal models for the blood concentrations of homocys-
teine, vitamin B6, vitamin B12, α-tocopherol or the sum of
2352 One-carbon metabolism biomarkers and risk of UCC
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Table 1. Baseline characteristics of urothelial cell carcinoma cases and their matched controls
Cases (n = 824) Controls9 (n = 824)
General characteristics
Men, n(%) 611 (74) 611 (74)
Women, n(%) 213 (26) 213 (26)
BMI (kg/m2) 26.6  4.01 26.4  3.8
Physical active2 (%) 42 43
Age at recruitment (y) 58.4  7.4 58.4  7.4
Smoking status
Never smokers (n, %) 156 (19) 316 (38)
Former smokers (n, %) 294 (36) 287 (35)
Lifetime number of cigarettes
(cig/day)
10.2  10.2 9.9  10.2
Smoking duration (y) 25.3  13.6 21.8  12.9
Age at start smoking (y) 17.9  5.6 19.0  6.6
Time since quitting smoking (y) 13.4  11.4 16.8  11.8
Current smokers (n, %) 374 (45) 221 (27)
Lifetime number of cigarettes
(cig/day)
14.1  9.3 11.7  8.8
Smoking duration (y) 38.7  10.0 36.1  11.6
Age at start smoking (y) 17.9  5.9 19.6  7.9
Exposure to occupational carcinogens (n, %)3
Heavy metals 168 (12) 159 (11)
Aromatic amines 132 (9) 115 (8)
Polycylic Aromatic Hydrocarbons
(PAH)
115 (8) 94 (7)
Environmental tobacco smoke 37 (3) 38 (3)
Educational level (n, %)
None or primary school 387 (47) 338 (41)
Technical/professional school 200 (24) 230 (28)
Secondary school 90 (11) 86 (10)
University degree 142 (17) 159 (20)
Not specified 5 (1) 11 (1)
Serum concentrations micronutrients (median, 5th - 95th percentile)
Folate (nmol/L) 14.9 (7.2–31.4)4 16.0 (7.9–34.9)
Homocysteine (μmol/L) 16.6 (9.4–26.3) 16.0 (8.7–25.6)
Vitamin B6 (μg/L) 37.5 (15.8–124.0) 40.1 (15.6–122.9)
Vitamin B12 (pmol/L) 275 (140–547) 270 (140–492)
Dietary factors
Total energy (kcal/d) 2,266.1  665.4 2,288.6  716.3
Energy from fat (kcal/d) 784.9  285.8 790.2  296.9
Energy from non-fat (kcal/d) 1,481.2  446.2 1,498.4  484.5
Alcohol consumption (g/d) 19.2  22.7 17.6  21.4
Red and processed meat (g/d) 96.9  56.7 95.2  61.7
Fresh fruits (g/d) 195.5  163.7 217.4  189.9
Total vegetables (g/d) 169.5  142.6 176.9  125.2
Dietary folate intake (μg/d) 291.2  106.9 302.6  132.6
Dietary vitamin B2 (mg/d) 2.0  0.63 2.04  0.78
Dietary vitamin B6 intake (mg/d) 1.92  0.80 1.91  0.77
Dietary vitamin B12 intake (μg/d) 7.9  6.0 7.4  4.5
(Continues)
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carotenoids (data not shown). Serum concentrations of homo-
cysteine, vitamin B6, or vitamin B12 were not related to UCC
risk (Table 2; Supporting Information Table S1). No evidence for
a quadratic relationship was found (data not shown). The posi-
tive and null associations persisted after exclusion of cases diag-
nosed during the ﬁrst 2 years of follow-up (data not shown).
For a halving in dietary folate levels, an increased risk was
seen for aggressive UCC in the smoking adjusted model (OR:
1.45; 95% CI: 1.03–2.04; Supporting Information Table 2)
which was attenuated in the fully adjusted model (OR: 1.26;
95% CI: 0.81–1.95; Table 3). No signiﬁcant heterogeneity by
tumour subtype was observed (p-heterogeneity = 0.07 and
0.14, respectively). Intakes of dietary vitamin B2, vitamin B6
and vitamin B12 were not associated with UCC risk (Table 3).
There was some indication that the association of dietary
folate and dietary vitamin B6 may be non-linear (P ≤ 0.05 for
a model with vs. without a quadratic term).
We further studied whether there was statistical interaction
between serum folate and smoking status in relation to UCC
risk. The elevated risk of UCC seemed only apparent for
current smokers with lowest folate concentrations compared
to never smokers with highest folate concentrations in ana-
lyses unadjusted (OR for lowest vs. highest quartile (ORQ1-Q4):
6.26; 95% CI: 3.62–10.81; p-interaction = 0.07; Table 4) and
adjusted (ORQ1-Q4: 2.02; 95% CI: 1.07–3.82; p-interaction =
0.11; Supporting Information Table 3) for smoking duration
and intensity. In all other groups, risks were not signiﬁcantly
elevated. These data suggest that there is statistical interaction
between serum folate and smoking status in relation to risk of
UCC. No interaction with smoking status was observed for
the associations of homocysteine, vitamin B6, and vitamin
B12 with risk of UCC. Interactions on a multiplicative scale
between serum folate and these three biomarkers were not sig-
niﬁcant (p-interaction>0.05). Further, no statistical interaction
was observed between all four biomarkers and alcohol intake,
gender or BMI in relation to UCC risk (p-interaction>0.05)
(data not shown).
Discussion
In this large prospective study, lower serum folate concentra-
tions were associated with an increased risk of UCC, in particu-
lar aggressive UCC. The positive association with lower serum
folate concentrations seemed only apparent in current smokers.
Dietary folate intake was associated with an increased risk of
aggressive UCC in the smoking adjusted models but this asso-
ciation was attenuated in the fully adjusted models. Other
nutrients involved in the one-carbon metabolism pathway,
i.e. serum homocysteine, vitamin B6, or vitamin B12, were
not associated with UCC risk.
Previous ﬁndings of the relation between dietary intake of
B-vitamins and the risk of bladder cancer have yielded incon-
sistent results. A meta-analysis observed an inverse association
between folate intake and bladder cancer risk in six case–
control studies (OR = 0.73; 95% CI 0.57–0.89), but not in
seven cohort studies (relative risk = 0.96; 95% CI 0.81–1.10)
(3). Also a recent cohort study found no association of dietary
intake of folate and other B-group vitamins with UCC risk,
and did not observe heterogeneity across UCC subtypes.27
Self-reported dietary folate intake may be a less accurate mea-
sure of folate status than blood folate concentrations, which
reﬂect both dietary and supplemental intakes and is directly
related to bioavailability. One case–control study from Taiwan
with 171 bladder cancer cases reported a decreased bladder
cancer risk with higher plasma folate concentrations (4). A
recent nested case–control study from Australia with 363 UCC
cases found no association between pre-diagnostic plasma folate
concentrations and UCC risk (5).
Table 1. Baseline characteristics of urothelial cell carcinoma cases and their matched controls (Continued)
Cases (n = 824) Controls9 (n = 824)
Cases only
Age at diagnosis 63.2  7.7 -
Time from blood draw to diagnosis (y) 4.6  2.8 -
Urothelial cell carcinomas (n,%)5
Aggressive6 390 (47) -
Non-aggressive7 374 (45) -
Unknown8 60 (8) -
1Mean  SD (all such values).
2Cambridge Physical Activity Index incorporates occupational and nonoccupational physical activity.
3Data were not available for Umea (Sweden), Norway, Naples (Italy), Utrecht (Netherlands), and France.
4Median; 5th – 95th percentile in parentheses (all such values).
5Includes urothelial cell papillomas and carcinomas (morphology codes 8,120 and 8,130, and behaviour coded as uncertain whether benign or malig-
nant, carcinoma in situ, and/or malignant) but excludes inverted papillomas (8,121/1).
6Includes all stage T1 or higher, carcinoma in situ, or WHO 1973 grade 3 carcinomas (including Ta grade 3).
7Includes all stage Ta grade 1 or Ta grade 2 carcinomas.
8Sixty urothelial cell carcinomas could not be classified as aggressive or nonaggressive urothelial cell carcinomas because of lack of information on
stage or grade.
9Controls were matched to cases by sex, age at baseline, study centre, date and time of blood collection, and fasting status.
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Folate plays an important role in DNA synthesis, repair, and
methylation.1 Low plasma folate concentrations may increase the
risk of UCC and other cancers by inducing DNA hypomethyla-
tion, potentially leading to dysregulation of proto-oncogenes and
tumour suppressor genes.1 UCC is a complex disease with
etiologic heterogeneity and appears to occur via distinct
molecular pathways. Interestingly, besides a differential asso-
ciation of global DNA methylation with UCC subtypes,13,14 a
high-throughput DNA methylation analysis of UCC tumours
also revealed distinct methylation patterns.28 Non-aggressive
Table 2. Serum concentrations of folate, homocysteine, vitamin B6 and B12 and the risk of urothelial cell carcinomas1
No. of cases/
controls Total UCC2
No. of cases/
controls Aggressive UCC2
No. of cases/
controls Non-aggressive UCC2
Folate (nmol/L)3
≤ 11.92 245/198 1.37 (0.97–1.92) 115/83 1.66 (1.02–2.70) 116/106 0.97 (0.58–1.64)
11.95–16.02 205/199 1.30 (0.94–1.79) 91/100 1.23 (0.76–2.00) 98/85 1.24 (0.75–2.04)
16.03–21.32 174/202 1.04 (0.76–1.42) 86/91 1.12 (0.70–1.79) 74/98 0.81 (0.50–1.32)
≥ 21.33 175/200 1.00 84/102 1.00 77/76 1.00
p for trend4 0.04 0.04 0.69
Continuous after log2-transformation5 1.18 (0.98–1.43) 1.34 (1.02–1.75) 1.03 (0.78–1.37)
p for heterogeneity6 0.19
Homocysteine (μmol/L)7
≤ 13.32 177/200 0.80 (0.57–1.15) 72/85 0.80 (0.48–1.34) 88/92 1.02 (0.60–1.72)
13.33–15.94 176/198 0.74 (0.54–1.03) 79/92 0.65 (0.41–1.03) 83/91 0.90 (0.54–1.50)
15.95–19.01 215/202 0.96 (0.72–1.28) 110/113 0.79 (0.53–1.18) 92/76 1.38 (0.87–2.20)
≥ 19.05 232/200 1.00 119/90 1.00 99/103 1.00
p for trend4 0.16 0.31 0.80
Continuous after log2-transformation5 0.85 (0.65–1.11) 0.84 (0.56–1.25) 0.87 (0.60–1.26)
p for heterogeneity6 0.89
Vitamin B6 (μg/L)8
≤ 27.96 226/186 1.11 (0.79–1.56) 95/89 1.00 (0.62–1.63) 115/82 1.17 (0.71–1.94)
28.04–39.86 184/187 1.13 (0.81–1.58) 91/76 1.50 (0.92–2.45) 78/100 0.79 (0.48–1.31)
39.96–58.41 173/187 1.03 (0.75–1.43) 81/89 1.04 (0.65–1.67) 75/83 0.90 (0.55–1.47)
≥ 59.24 166/189 1.00 82/95 1.00 76/79 1.00
p for trend4 0.48 0.72 0.58
Continuous after log2-transformation5 0.96 (0.85–1.09) 0.94 (0.78–1.13) 0.96 (0.80–1.15)
p for heterogeneity6 0.85
Vitamin B12 (pmol/L)9
≤ 214 204/195 0.94 (0.69–1.28) 99/99 0.86 (0.54–1.37) 88/81 0.92 (0.58–1.44)
215–270 182/204 0.84 (0.61–1.15) 90/99 0.77 (0.48–1.23) 78/89 0.87 (0.54–1.39)
271–346 207/201 1.02 (0.76–1.37) 94/88 1.03 (0.68–1.57) 95/98 0.92 (0.59–1.44)
≥ 347 212/205 1.00 97/94 1.00 105/98 1.00
p for trend4 0.53 0.40 0.67
Continuous after log2-transformation5 0.87 (0.71–1.05) 0.88 (0.67–1.17) 0.81 (0.61–1.09)
p for heterogeneity6 0.69
1The Total UCC group includes urothelial cell papillomas and carcinomas (morphology codes 8,120 and 8,130, and behaviour coded as uncertain
whether benign or malignant, carcinoma in situ, and/or malignant) but excludes inverted papillomas (8,121/1). The Aggressive UCC category includes
all stage T1 or higher, carcinoma in situ, or WHO 1973 grade 3 carcinomas (including Ta grade 3). The group Non-aggressive UCC category includes all
stage Ta grade 1 or Ta grade 2 carcinomas.
2All values are odds ratios; 95% CIs in parentheses. Analyses were matched for age at blood collection, study centre, sex, date and time of blood collec-
tion, and fasting status and further adjusted for smoking status, duration and intensity of smoking, energy intake, red meat intake, processed meat
intake, alcohol intake, physical activity, BMI, educational level.
3For 46 cases and/or controls information is lacking on serum folate.
4Test for trend was performed using the median log2 value of each quartile.
5Values were derived from adjusted models as described in footnote 2 for risk associated with a halving in serum concentration.
6Likelihood ratio test of heterogeneity, testing for a common association across subtypes.
7For 44 cases and/or controls information is lacking on serum homocysteine.
8For 146 cases and/or controls information is lacking on serum vitamin B6.
9For 34 cases and/or controls information is lacking on serum vitamin B12.
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tumours displayed a hypomethylated phenotype whereas
invasive tumours showed widespread hypermethylation,
conﬁrming that the two pathways differ epigenetically.28 Due
to the relatively large number of cases in our study, we were
able to analyse prognostic subgroups of UCC according to
tumour aggressiveness. We found stronger associations for
folate with aggressive UCC, which may have been missed in
previous studies limited to total UCC. It is known that
aggressive, high-grade bladder tumours frequently show
defects in the TP53 and RB tumour suppressor genes.29 In
laboratory models, folate deﬁciency appears to induce p53
mutations.1 Moreover, even in the absence of genomic hypo-
methylation, folate depletion has been shown to induce
hypomethylation in the coding region of p53 while supple-
mental folate has been shown to revert the hypomethylation
of this region.1 This potential mechanism suggests that folate
Table 3. Dietary folate, vitamins B2, B6 and B12 and the risk of urothelial cell carcinomas1
No. of cases/
controls Total UCC2
No. of cases/
controls Aggressive UCC2
No. of cases/
controls Non-aggressive UCC2
Dietary folate (μg/d)
≤ 226.74 225/204 1.18 (0.76–1.84) 98/80 1.42 (0.78–2.59) 110/107 1.00 (0.56–1.81)
227.40–282.19 216/206 1.17 (0.81–1.69) 104/98 1.25 (0.76–2.06) 99/98 1.10 (0.65–1.84)
282.46–350.55 201/206 1.19 (0.86–1.65) 98/107 1.28 (0.80–2.03) 85/83 1.12 (0.68–1.83)
≥ 350.71 180/206 1.00 88/103 1.00 80/86 1.00
p for trend3 0.47 0.27 0.99
Continuous after log2-transformation4 1.03 (0.73–1.47) 1.26 (0.81–1.95) 0.85 (0.53–1.36)
p for heterogeneity5 0.14
Dietary vitamin B2 (mg/d)
≤ 1.43 233/205 1.15 (0.76–1.75) 110/103 1.12 (0.63–1.97) 103/86 1.11 (0.63–1.96)
1.41–1.78 181/206 0.87 (0.61–1.25) 96/88 1.15 (0.71–1.88) 71/104 0.63 (0.37–1.07)
1.78–2.25 207/205 1.10 (0.80–1.51) 92/90 1.22 (0.77–1.94) 100/97 1.02 (0.64–1.63)
≥ 2.25 201/206 1.00 90/107 1.00 100/87 1.00
p for trend3 0.68 0.69 0.87
Continuous after log2-transformation4 0.91 (0.67–1.25) 0.96 (0.64–1.43) 0.83 (0.55–1.26)
p for heterogeneity5 0.57
Dietary vitamin B6 (mg/d)
≤ 1.55 203/205 0.98 (0.61–1.59) 91/90 1.08 (0.58–1.99) 92/100 0.84 (0.45–1.60)
1.56–1.95 210/205 1.16 (0.78–1.71) 97/91 1.27 (0.75–2.14) 101/99 1.15 (0.67–1.98)
1.96–2.40 232/207 1.24 (0.88–1.74) 121/104 1.42 (0.89–2.26) 94/86 1.19 (0.72–1.96)
≥ 2.40 177/205 1.00 79/103 1.00 87/89 1.00
p for trend3 0.80 0.95 0.53
Continuous after log2-transformation4 0.84 (0.56–1.26) 0.87 (0.53–1.42) 0.79 (0.47–1.34)
p for heterogeneity5 0.72
Dietary vitamin B12 (μg/d)
≤ 4.76 182/205 0.79 (0.53–1.16) 87/98 0.71 (0.42–1.21) 81/92 0.92 (0.53–1.59)
4.76–6.58 211/205 0.94 (0.67–1.33) 95/95 0.86 (0.53–1.40) 94/87 1.06 (0.65–1.74)
6.63–8.93 194/206 0.92 (0.67–1.27) 99/104 0.97 (0.62–1.51) 81/94 0.80 (0.50–1.28)
≥ 8.91 235/206 1.00 107/91 1.00 118/101 1.00
p for trend3 0.26 0.19 0.90
Continuous after log2-transformation4 0.84 (0.70–1.02) 0.80 (0.62–1.04) 0.85 (0.65–1.11)
p for heterogeneity5 0.73
1The Total UCC group includes urothelial cell papillomas and carcinomas (morphology codes 8,120 and 8,130, and behaviour coded as uncertain
whether benign or malignant, carcinoma in situ, and/or malignant) but excludes inverted papillomas (8,121/1). The Aggressive UCC category includes
all stage T1 or higher, carcinoma in situ, or WHO 1973 grade 3 carcinomas (including Ta grade 3). The group Non-aggressive UCC category includes all
stage Ta grade 1 or Ta grade 2 carcinomas.
2All values are odds ratios; 95% CIs in parentheses. Analyses were matched for age at blood collection, study centre, sex, date and time of blood collec-
tion, and fasting status and further adjusted for smoking status, duration and intensity of smoking, energy intake, red meat intake, processed meat
intake, alcohol intake, physical activity, BMI, educational level.
3Test for trend was performed using the median log2 value of each quartile.
4Values were derived from adjusted models as described in footnote 2 for risk associated with a halving in dietary intake.
5Likelihood ratio test of heterogeneity, testing for a common association across subtypes.
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can modulate aggressive bladder carcinogenesis through DNA
methylation. Within the EPIC cohort, associations for plasma
carotenoids were particularly driven by aggressive UCC as
well.12 However, the precise mechanisms underlying the associ-
ation with aggressive bladder cancer risk remain unresolved.
Efﬁcient one-carbon metabolism requires not only folate, but
also vitamins B2, B6 and B12. These nutrients interact metabol-
ically with folate in the one-carbon metabolism process, and
may inﬂuence cancer risk.1 Our study found, however, no
evidence for an association of blood concentrations and
dietary intake of vitamins B2, B6 and B12 with UCC risk.
Smoking may affect B-vitamin status and reduce bioavail-
ability of folate. Current smokers have lower circulating folate
concentrations, even after correction for folate intake. This sug-
gests that smoking alters the systemic uptake or metabolism of
folate.23,24 Previous ﬁndings suggest that the combined effects
of smoking with decreased folate levels can induce increased
chromosomal damage. The higher proportion of cells with
chromosome aberrations in cigarette smokers was attributed to
lower folate levels in smokers compared to non-smokers.30,31
Thus, DNA damage induced by smoking may be modulated by
the folate metabolic pathway. In the present study, a statistically
signiﬁcant increased risk of UCC was only observed in current
smokers with lowest folate concentrations. Consistent results
were seen in a case–control study from the United States where
current smokers with lower folate intake tended to have a
greater risk of bladder cancer compared to current smokers
with higher folate intake.32 If an effect of serum folate exists,
our study suggests that it is particularly prominent in smokers
with lowest folate concentrations. No statistical interaction with
alcohol intake, gender, and BMI was observed. However, the
observed associations should be interpreted with caution because
we conducted multiple comparisons and because residual con-
founding by smoking cannot be excluded.
Diets with a low intake of fruits and vegetables, leading to
insufﬁcient folate intake and serum levels, may reﬂect an
unhealthy lifestyle.33 In our study, participants with lower
serum folate concentrations tended to have an unhealthier life-
style. However, this is unlikely to explain the observed associa-
tions of serum folate with UCC risk, since risk estimates
remained unchanged after adjustment for several lifestyle fac-
tors. On the other hand, the observed associations may reﬂect
other unmeasured lifestyle factors associated with both low
serum folate concentrations and high risk of UCC. Further,
exposure to potential risk factors may have changed during
follow-up, leading to residual confounding. We could not take
this into account, as replicate measurements were not available.
Higher folate concentrations may also be a marker of a con-
certed effect of multiple bioactive compounds in fruit and
vegetables. Although folate sources are not restricted to fruit
and vegetables, blood folate concentrations may be a useful
biomarker for the intake of fruit and vegetables in popula-
tions consuming unfortiﬁed foods.34 At the time of data col-
lection, no European country had introduced mandatory
folic acid fortiﬁcation, although voluntary fortiﬁcation was
accepted in some countries, including France and the UK.35
The use of dietary supplements could also affect serum concen-
trations of micronutrients. However, a study on the use of die-
tary supplements in a sub-sample of the EPIC cohort indicated
that folic acid supplements were not frequently consumed at
the time of data collection.36 Also, no substantial change in risk
estimates was observed by simple adjustment for dietary sup-
plement use (yes vs. no) (data not shown). Therefore, serum
folate in our study seems to be largely determined by natural
folates from foods. Despite the low correlation between serum
concentrations and dietary intakes of folate (0.22), we observed
quite similar risk estimates in the smoking adjusted but not the
fully adjusted models. The weak correlation may be explained
by errors in the food composition table from which folate was
derived and biases in the assessment of dietary intake. Other
explanations may be related to the bioavailability of folate that
is inﬂuenced by several factors including smoking.
Table 4. Joint effects of smoking status and serum folate
Smoking status
Never smokers Former smokers Current smokers
No. of cases/
controls Total UCC1,2
No. of cases/
controls Total UCC1,2
No. of cases/
controls Total UCC1,2 P-interaction3
Serum folate
(nmol/L)
≤ 11.92 35/74 0.94 (0.52–1.71) 63/64 2.36 (1.34–4.17) 148/61 6.26 (3.62–10.81)
11.95–16.02 46/76 1.33 (0.77–2.28) 77/67 2.83 (1.65–4.87) 82/56 3.33 (1.93–5.75)
16.03–21.32 29/82 0.72 (0.41–1.28) 72/65 2.54 (1.48–4.37) 74/55 3.39 (1.94–5.90)
≥ 21.33 42/77 1.00 75/80 2.05 (1.19–3.52) 58/44 2.88 (1.64–5.06) 0.07
1The Total UCC group includes urothelial cell papillomas and carcinomas (morphology codes 8,120 and 8,130, and behaviour coded as uncertain
whether benign or malignant, carcinoma in situ, and/or malignant) but excludes inverted papillomas (8,121/1).
2All values are odds ratios; 95% CIs in parentheses. Analyses were matched for age at blood collection, study centre, sex, date and time of blood collec-
tion, and fasting status.
3Statistical interaction on a multiplicative scale was tested by introducing a product term between serum one-carbon metabolism biomarkers (quartiles)
and smoking status in the model.
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The strengths of our study include its prospective design, a
relatively large number of incident UCC cases, the wide range
in blood concentrations of one-carbon metabolism related
nutrients, and the collection of blood samples before cancer
diagnosis. However, some limitations of the present study need
to be discussed. Our analyses were based on single measure-
ments of nutrients involved in the one-carbon metabolism at
baseline, assuming stable serum concentrations during follow-
up. Blood concentrations may differ over time because of
day-to-day variation and long-term changes within persons,
leading to an attenuation of the associations. A reliability study
in a subsample of the two Dutch cohorts within EPIC showed
that over 2–5 years, serum homocysteine and vitamin B12 were
highly reliable biomarkers with intraclass correlation coefﬁcients
(ICC) of 0.91 and 0.75, respectively.37 The ICC for serum folate
was 0.45 and for vitamin B6 was 0.38. These measures should
be reliable enough to detect moderate associations. Serum folate
is an indicator of more recent folate intake, while red blood cell
folate is considered to reﬂect average concentration over the
erythrocyte life span (about 120 days).38,39 As red blood cells
are less subject to short-term dietary changes and reﬂect long-
term folate status, the observed associations for serum folate
may be even stronger for red blood cell folate. We did not have
information on polymorphisms in MTHFR or other relevant
genes, which play an important role in DNA methylation and
are determinants of serum folate concentrations.40 Possible sta-
tistical interaction between serum folate concentrations and
polymorphisms in MTHFR in relation to UCC risk needs to be
investigated.
In conclusion, our study suggests that lower serum folate
concentrations may increase the risk of UCC, in particular
aggressive UCC. This increased risk was only seen in current
smokers. However, residual confounding by smoking cannot
be excluded and conﬁrmation in prospective studies with mul-
tiple measurements is warranted.
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